ArticleThe Laryngoscope2021
The Interconnections of Mal de Débarquement Syndrome and Vestibular Migraine.
Article in The Laryngoscope, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Assessing the synergistic effectiveness of intermittent theta burst stimulation and the vestibular ocular reflex rehabilitation protocol in the treatment of Mal de Debarquement Syndrome: a randomised controlled trial.Journal of neurology · 2024Trial
- Vestibular migraine vs. migraine only: integrated transcriptome-clinical profiling reveals shared inflammation and divergent metabolic pathways for targeted therapy.European journal of medical research · 2025Article
- Persistent Oscillating Vertigo From Extracranial Venous Compression.Otology & neurotology open · 2025Article
- Potential lesson from a model-based exploration on treatment effect heterogeneity of mal de débarquement syndrome.Frontiers in neurology · 2025Article
- The utility of artificial vestibular stimulation in decoding the pathophysiology of mal de débarquement syndrome.Frontiers in neurology · 2025Article
- Beyond Vertigo: Vestibular, Aural, and Perceptual Symptoms in Vestibular Migraine.Current pain and headache reports · 2024Review
- Subjective and objective responses to caloric stimulation help separate vestibular migraine from other vestibular disorders.Journal of neurology · 2024Article
- Symptom reduction in mal de débarquement syndrome with attenuation of the velocity storage contribution in the central vestibular pathways.Frontiers in rehabilitation sciences · 2024Article
- What's in a Name? Chronic Vestibular Migraine or Persistent Postural Perceptual Dizziness?Brain sciences · 2023Review
- Neurological update: neuro-otology 2023.Journal of neurology · 2023Article
- Migraine management for the otolaryngologist.Laryngoscope investigative otolaryngology · 2023Review
- Vestibular Migraine.Current neurology and neuroscience reports · 2022Review
- Visual disorders and mal de debarquement syndrome: a potential comorbidity questionnaire-based study.Future science OA · 2022Article
- Toward personalized medicine for mal de débarquement syndrome.Frontiers in neurologyArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectives/hypothesisMal de débarquement syndrome (MDDS) is characterized by a persistent rocking sensation, as though on a boat. It may occur following exposure to passive motion (motion-triggered MDDS [MT-MDDS]), or spontaneously (spontaneous-onset MDDS [SO-MDDS]). This study investigated the characteristics of MDDS patients with vestibular migraine (MDDS-VM) to those without (MDDS-O). STUDY
designRetrospective review.
methodsRetrospective, single-center study of 62 patients with MDDS. Clinical characteristics, Dizziness Handicap Inventory (DHI), Migraine Disability Assessment Score (MIDAS), job impact, and optimal treatment(s) were studied.
resultsThere were 23 MDDS-O (19 women), and 39 MDDS-VM (35 women) patients. Comparisons between MDDS-VM and MDDS-O showed significant differences in age of onset (41 vs. 52 years, P = .005), interictal visually induced dizziness (89.7% vs. 30.4%, P < .001), interictal head motion-induced dizziness (87.2% vs. 47.8%, P = .001), other vestibular sensations (59% vs. 13%, P < .001), interictal aural symptoms (25.6% vs. 0%, P = .008), number of interictal symptoms (4.3 vs. 2.3, P < .001), total DHI score (54.9 vs. 38.1, P = .005), DHI-P (physical domain) score (16.1 vs. 10, P = .004), DHI-F (functional domain) score (20.9 vs. 15.7, P = .016 MIDAS (4.6 vs. 32, P = .002), and job resignations (23.2% vs. 5%, P = .016). On the other hand, between-group comparisons for MT-MDDS and SO-MDDS did not reveal any significant differences whatsoever. For optimal treatment, venlafaxine was the most used (27.3%) in all groups. For MDDS-VM, antiepileptic drugs and migraine preventive vitamins were also useful in relieving symptoms.
conclusionsMDDS-VM patients appear to be more disabled than MDDS-O, in terms of severity of dizziness, job impact, and number of symptoms, but have good potential for improvement, particularly with migraine prophylactic treatment. LEVEL OF EVIDENCE: 3 Laryngoscope, 131:E1653-E1661, 2021.
Indexed as
Identifiers
33135784What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.